D. E. Shaw & Co., Inc. Genprex, Inc. Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.82 - $3.5 $227,925 - $438,319	-125,234 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.21 - $2.7 $47,753 - $106,558	39,466 Added 46.01%	125,234 $164,000
Q3 2021 Nov 15, 2021	BUY	$2.59 - $3.36 $148,616 - $192,800	57,381 Added 202.14%	85,768 $230,000
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.87 $88,283 - $138,244	28,387 New	28,387 $95,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $112M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.